A new study “New Zealand Meningococcal Market Research 2019” commissioned by GSK, has found a lack of understanding about the need to vaccinate against the disease.
New Zealand is heading into “peak season” for the devastating disease and it cannot be overlooked due to the coronavirus pandemic. Expert say, “People aged 13 to 29 who were immunised during the last meningococcal disease epidemic are entering a “high risk” age group and need to be re-vaccinated to maintain protection”.